X is CH:

R² is H, alkyl, alkoxy, halogen, amino or substituted amino;

R^{2a}, R^{2b} and R^{2c} are the same or different and are selected from H, alkyl, alkoxy, halogen, amino or substituted amino;

Y is CO_2R^4 where R^4 is H or alkyl, or a prodrug ester or Y is a C-linked 1-tetrazole, a phosphinic acid of the structure $P(O)(OR^{4a})R^5$ where R^{4a} is H or a prodrug ester, R^5 is alkyl or aryl or a phosphonic acid of the structure $P(O)(OR^{4a})_2$ where R^{4a} is H or a prodrug ester;

or stereoisomers thereof, prodrug esters thereof, and pharmaceutically acceptable salts thereof, and a lipid-lowering agent, a lipid modulating agent, an antidiabetic agent, an anti-obesity agent, an antihypertensive agent which is other than a diuretic, a platelet aggregation inhibitor, and/or an antiosteoporosis

agent. --

Please add the following claims

-- 57. A pharmaceutical combination comprising a compound which has the structure



$$\begin{array}{c|c}
R^{2a} & R^{2b} \\
R^$$

wherein x is 1, 2, 3 or 4; m is 1 or 2; n is 1 or 2;

Q is C or N;

A is O or S;

Z is O or a bond;

R¹ is H or lower alkyl;

X is CH;

R² is H, alkyl, alkoxy, halogen, amino or substituted amino;

R^{2a}, R^{2b} and R^{2c} are the same or different and are selected from H, alkyl, alkoxy, halogen, amino or substituted amino;

R³ is aryloxycarbonyl, alkyloxycarbonyl, alkynyloxycarbonyl, alkenyloxycarbonyl, alkyl(halo)aryloxycarbonyl, alkyloxy(halo)aryloxycarbonyl, cycloalkylaryloxycarbonyl, cycloalkyloxyaryloxycarbonyl, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkoxycarbonylamino, aryloxycarbonylamino, heteroaryloxycarbonylamino, alkylsulfonyl, alkenylsulfonyl, heteroaryloxycarbonyl, cycloheteroalkyloxycarbonyl, heteroarylalkenyl, hydroxyalkyl, alkoxy, alkoxyaryloxycarbonyl, arylalkyloxycarbonyl, alkylaryloxycarbonyl, alkynyloxycarbonyl, haloalkoxyaryloxycarbonyl, alkoxycarbonylaryloxycarbonyl, aryloxyarylalkyloxycarbonyl, aryloxyarylalkyloxycarbonyl, aryloxyarylalkyloxycarbonyl, arylalkenyloxycarbonyl, arylalkenylsulfonyl, heteroarylalkyloxyarylalkyl, arylalkenylarylalkyl, arylalkenylarylalkyl, arylalkenylarylalkyl, arylalkenylarylalkyl, arylalkenylarylalkyl, arylalkenylarylalkyl, arylalkenylarylalkyl, arylalkenylarylalkyl, or polyhaloalkylaryloxycarbonyl;

Y is CO₂R⁴ where R⁴ is H or alkyl, or a prodrug ester or Y is a C-linked 1-tetrazole, a phosphinic acid of the structure P(O)(OR^{4a})R⁵ where R^{4a} is H or a prodrug ester, R⁵ is alkyl or aryl or a phosphonic acid of the structure P(O)(OR^{4a})₂ where R^{4a} is H or a prodrug ester;

or stereoisomers thereof, prodrug esters thereof, and pharmaceutically acceptable salts thereof, and an antihypertensive agent which is a diuretic. --

-- 58. The combination as defined in Claim 57 wherein the diuretic is hydrochlorothiazide, torasemide, furosemide, spironolactone or indapamide. --